685 related articles for article (PubMed ID: 20530286)
1. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.
Klechevsky E; Flamar AL; Cao Y; Blanck JP; Liu M; O'Bar A; Agouna-Deciat O; Klucar P; Thompson-Snipes L; Zurawski S; Reiter Y; Palucka AK; Zurawski G; Banchereau J
Blood; 2010 Sep; 116(10):1685-97. PubMed ID: 20530286
[TBL] [Abstract][Full Text] [Related]
2. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.
von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J
J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240
[TBL] [Abstract][Full Text] [Related]
3. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production.
Meyer-Wentrup F; Benitez-Ribas D; Tacken PJ; Punt CJ; Figdor CG; de Vries IJ; Adema GJ
Blood; 2008 Apr; 111(8):4245-53. PubMed ID: 18258799
[TBL] [Abstract][Full Text] [Related]
4. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.
Idoyaga J; Lubkin A; Fiorese C; Lahoud MH; Caminschi I; Huang Y; Rodriguez A; Clausen BE; Park CG; Trumpfheller C; Steinman RM
Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2384-9. PubMed ID: 21262813
[TBL] [Abstract][Full Text] [Related]
5. Efficient generation of a monoclonal antibody against the human C-type lectin receptor DCIR by targeting murine dendritic cells.
Heidkamp GF; Neubert K; Haertel E; Nimmerjahn F; Nussenzweig MC; Dudziak D
Immunol Lett; 2010 Aug; 132(1-2):69-78. PubMed ID: 20566350
[TBL] [Abstract][Full Text] [Related]
6. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
[TBL] [Abstract][Full Text] [Related]
7. DCIR interacts with ligands from both endogenous and pathogenic origin.
Bloem K; Vuist IM; van den Berk M; Klaver EJ; van Die I; Knippels LM; Garssen J; García-Vallejo JJ; van Vliet SJ; van Kooyk Y
Immunol Lett; 2014; 158(1-2):33-41. PubMed ID: 24239607
[TBL] [Abstract][Full Text] [Related]
8. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets.
Kastenmüller K; Wille-Reece U; Lindsay RW; Trager LR; Darrah PA; Flynn BJ; Becker MR; Udey MC; Clausen BE; Igyarto BZ; Kaplan DH; Kastenmüller W; Germain RN; Seder RA
J Clin Invest; 2011 May; 121(5):1782-96. PubMed ID: 21540549
[TBL] [Abstract][Full Text] [Related]
9. DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production.
Meyer-Wentrup F; Cambi A; Joosten B; Looman MW; de Vries IJ; Figdor CG; Adema GJ
J Leukoc Biol; 2009 Mar; 85(3):518-25. PubMed ID: 19028959
[TBL] [Abstract][Full Text] [Related]
10. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
[TBL] [Abstract][Full Text] [Related]
11. Targeting dendritic cells in humanized mice receiving adoptive T cells via monoclonal antibodies fused to Flu epitopes.
Graham JP; Authie P; Yu CI; Zurawski SM; Li XH; Marches F; Flamar AL; Acharya A; Banchereau J; Palucka AK
Vaccine; 2016 Sep; 34(41):4857-4865. PubMed ID: 27595442
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
[TBL] [Abstract][Full Text] [Related]
13. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.
Schreibelt G; Klinkenberg LJ; Cruz LJ; Tacken PJ; Tel J; Kreutz M; Adema GJ; Brown GD; Figdor CG; de Vries IJ
Blood; 2012 Mar; 119(10):2284-92. PubMed ID: 22234694
[TBL] [Abstract][Full Text] [Related]
14. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
[TBL] [Abstract][Full Text] [Related]
15. APCs express DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif.
Bates EE; Fournier N; Garcia E; Valladeau J; Durand I; Pin JJ; Zurawski SM; Patel S; Abrams JS; Lebecque S; Garrone P; Saeland S
J Immunol; 1999 Aug; 163(4):1973-83. PubMed ID: 10438934
[TBL] [Abstract][Full Text] [Related]
16. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
[TBL] [Abstract][Full Text] [Related]
17. Murine Langerin+ dermal dendritic cells prime CD8+ T cells while Langerhans cells induce cross-tolerance.
Flacher V; Tripp CH; Mairhofer DG; Steinman RM; Stoitzner P; Idoyaga J; Romani N
EMBO Mol Med; 2014 Sep; 6(9):1191-204. PubMed ID: 25085878
[TBL] [Abstract][Full Text] [Related]
18. Enhanced dendritic cell-induced immune responses mediated by the novel C-type lectin receptor mDCAR1.
Kaden SA; Kurig S; Vasters K; Hofmann K; Zaenker KS; Schmitz J; Winkels G
J Immunol; 2009 Oct; 183(8):5069-78. PubMed ID: 19786536
[TBL] [Abstract][Full Text] [Related]
19. CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses.
Hutten TJ; Thordardottir S; Fredrix H; Janssen L; Woestenenk R; Tel J; Joosten B; Cambi A; Heemskerk MH; Franssen GM; Boerman OC; Bakker LB; Jansen JH; Schaap N; Dolstra H; Hobo W
J Immunol; 2016 Oct; 197(7):2715-25. PubMed ID: 27566820
[TBL] [Abstract][Full Text] [Related]
20. Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28.
Pufnock JS; Cigal M; Rolczynski LS; Andersen-Nissen E; Wolfl M; McElrath MJ; Greenberg PD
Blood; 2011 Jun; 117(24):6542-51. PubMed ID: 21493800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
